Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ABIO

ABIO - ARCA biopharma Inc Stock Price, Fair Value and News

$21.20+0.86 (+4.23%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ABIO Price Action

ABIO RSI Chart

ABIO Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-10.35

Price/Sales (Trailing)

544.76

EV/EBITDA

-47.37

Price/Free Cashflow

-12.43

ABIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ABIO Fundamentals

ABIO Revenue

Revenue (TTM)

1.9M

ABIO Earnings

Earnings (TTM)

-101.6M

Earnings Growth (Yr)

-5.78%

Earnings Growth (Qtr)

-23.21%

ABIO Profitability

EBT Margin

-1053.70%

Return on Equity

-20.88%

Return on Assets

-19.96%

Free Cashflow Yield

-8.04%

ABIO Investor Care

Shares Dilution (1Y)

38.32%

Diluted EPS (TTM)

2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0M1.9M00
20231.1M1.5M1.8M2.0M
2022083.0K302.0K672.0K
20216.0K7.0K10.0K13.0K
2020158.0K112.0K63.0K28.0K
2019159.0K164.0K174.0K172.0K
2018163.0K167.0K163.0K162.0K
2017193.0K185.0K176.0K167.0K
201634.0K79.0K128.0K169.0K
20156.0K6.0K8.0K14.0K
20146.0K7.0K7.0K7.0K
201304.0K6.0K6.0K
201203.0K4.0K0
2011572.8K382.5K192.3K2.0K
2010000763.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About ARCA biopharma Inc

ABIO
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.
 CEO
 WEBSITEarcabio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

ARCA biopharma Inc Frequently Asked Questions

What is the ticker symbol for ARCA biopharma Inc? What does ABIO stand for in stocks?

ABIO is the stock ticker symbol of ARCA biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ARCA biopharma Inc (ABIO)?

As of Fri Oct 31 2025, market cap of ARCA biopharma Inc is 1.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABIO stock?

You can check ABIO's fair value in chart for subscribers.

Is ARCA biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether ABIO is over valued or under valued. Whether ARCA biopharma Inc is cheap or expensive depends on the assumptions which impact ARCA biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABIO.

What is ARCA biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 31 2025, ABIO's PE ratio (Price to Earnings) is -10.35 and Price to Sales (PS) ratio is 544.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABIO PE ratio will change depending on the future growth rate expectations of investors.